141 related articles for article (PubMed ID: 2068563)
1. Deficient fibrinolytic response in patients with Raynaud's phenomenon and its correction with defibrotide.
Cimminiello C; Milani M; Pietra A; Rossi F; Aloisio M; Nazzari M; Bonfardeci G
Semin Thromb Hemost; 1991; 17 Suppl 1():106-11. PubMed ID: 2068563
[TBL] [Abstract][Full Text] [Related]
2. Fibrinolytic effects of defibrotide in atherosclerotic patients.
Patrassi GM; Sartori MT; Viero ML; Scapinello MP; Boeri G; Girolami A
Semin Thromb Hemost; 1991; 17 Suppl 1():101-5. PubMed ID: 2068562
[TBL] [Abstract][Full Text] [Related]
3. [t-PA and PAI in patients with Raynaud's syndrome in treatment with a stable prostacyclin analog].
Pola P; de Martini D; Gerardino L
Angiologia; 1992; 44(2):62-6. PubMed ID: 1378247
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, multicenter, placebo-controlled, dose comparison study of orally administered defibrotide: preliminary results in patients with peripheral arterial disease.
Strano A; Fareed J; Sabbá C; Albano O; Allegra C; Carlizza A; Binaghi F; Fronteddu F; Del Guercio R; Arpaia MR
Semin Thromb Hemost; 1991; 17 Suppl 2():228-34. PubMed ID: 1948094
[TBL] [Abstract][Full Text] [Related]
5. [Use of defibrotide in the treatment of Raynaud's phenomenon associated with progressive systemic sclerosis or essential mixed cryoglobulinemia].
Ranieri G; De Mitrio V; Petronelli M; Ancona A; Dammacco F
Clin Ter; 1988 Sep; 126(5):335-43. PubMed ID: 2973963
[No Abstract] [Full Text] [Related]
6. Defibrotide blunts the prothrombotic effect of thalidomide on endothelial cells.
Echart CL; Somaini S; Distaso M; Palumbo A; Richardson PG; Fareed J; Iacobelli M
Clin Appl Thromb Hemost; 2012; 18(1):79-86. PubMed ID: 21733935
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of tissue plasminogen activator inhibitor by defibrotide in atherosclerotic patients.
Violi F; Ferro D; Alessandri C; Quintarelli C; Saliola M; Balsano F
Semin Thromb Hemost; 1989 Apr; 15(2):226-9. PubMed ID: 2501872
[TBL] [Abstract][Full Text] [Related]
8. Clinical trials with defibrotide in vascular disorders.
Cimminiello C
Semin Thromb Hemost; 1996; 22 Suppl 1():29-34. PubMed ID: 8807726
[TBL] [Abstract][Full Text] [Related]
9. The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity.
Echart CL; Graziadio B; Somaini S; Ferro LI; Richardson PG; Fareed J; Iacobelli M
Blood Coagul Fibrinolysis; 2009 Dec; 20(8):627-34. PubMed ID: 19809307
[TBL] [Abstract][Full Text] [Related]
10. Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man.
Coccheri S; Biagi G; Legnani C; Bianchini B; Grauso F
Eur J Clin Pharmacol; 1988; 35(2):151-6. PubMed ID: 3191933
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacology and mode of action of a new antithrombotic compound: Defibrotide.
Ulutin ON; Cizmeci G; Balkuv-Ulutin S
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):177-80. PubMed ID: 2459016
[TBL] [Abstract][Full Text] [Related]
12. Improvement of walking distance by defibrotide in patients with intermittent claudication--results of a randomized, placebo-controlled study (the DICLIS study). Defibrotide Intermittent CLaudication Italian Study.
Violi F; Marubini E; Coccheri S; Nenci GG
Thromb Haemost; 2000 May; 83(5):672-7. PubMed ID: 10823260
[TBL] [Abstract][Full Text] [Related]
13. Defibrotide enhances fibrinolysis in human endotoxemia - a randomized, double blind, crossover trial in healthy volunteers.
Schoergenhofer C; Buchtele N; Gelbenegger G; Derhaschnig U; Firbas C; Kovacevic KD; Schwameis M; Wohlfarth P; Rabitsch W; Jilma B
Sci Rep; 2019 Jul; 9(1):11136. PubMed ID: 31366975
[TBL] [Abstract][Full Text] [Related]
14. Effect of oral defibrotide on tissue-plasminogen activator and tissue-plasminogen activator inhibitor balance.
Violi F; Ferro D; Saliola M; Quintarelli C; Basili S; Balsano F
Eur J Clin Pharmacol; 1992; 42(4):379-83. PubMed ID: 1516602
[TBL] [Abstract][Full Text] [Related]
15. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
Fries R; Shariat K; von Wilmowsky H; Böhm M
Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
[TBL] [Abstract][Full Text] [Related]
16. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
17. Effects of defibrotide on physical performance and hemorheologic picture in patients with peripheral arteriopathy.
Marrapodi E; Leanza D; Giordano S; Nazzari M; Corsi C
Clin Trials Metaanal; 1994 Apr; 29(1):21-30. PubMed ID: 10150182
[TBL] [Abstract][Full Text] [Related]
18. Platelet activation, fibrinolytic activity and circulating immune complexes in Raynaud's phenomenon.
Kallenberg CG; Vellenga E; Wouda AA; The TH
J Rheumatol; 1982; 9(6):878-84. PubMed ID: 7161779
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Raynaud's phenomenon by fibrinolytic enhancement.
Jarrett PE; Morland M; Browse NL
Br Med J; 1978 Aug; 2(6136):523-5. PubMed ID: 698554
[TBL] [Abstract][Full Text] [Related]
20. [Nicardipine in the treatment of Raynaud's phenomenon].
Kahan A; Amor B; Menkès CJ
Rev Rhum Mal Osteoartic; 1987 Jun; 54(6):487-90. PubMed ID: 3303287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
